To describe the transcriptome profile of patients with VHD, microRNAs will be extracted from platelet-free plasma and frozen valve fragments [59 (link), 60 (link)]. The miRNeasy Serum/Plasma and miRNeasy Tissue/Cells kits will be used for miRNA extraction according to the manufacturers’ protocols (Qiagen, Hilden, Germany). Targeted and untargeted transcriptome analysis will be used to quantify dysregulated miRNAs [59 (link)–62 (link)]. High-throughput techniques will be used to sequence the extracted miRNAs. Integrative bioinformatics will be used to determine the mRNAs targeted by the altered miRNAs in RHD and AS and correlate them to proteomics and metabolomics biomarkers [59 (link)–62 (link)]. Transcriptomic biomarkers with a significant q value (q <0.05 will be considered important.
Free full text: Click here